🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

14 recruiting trials

for Developmental and Epileptic Encephalopathy

BMB-101 in Absence Epilepsy and DEE NCT06401538Phase 25 sites📍 Randwick📍 Herston📍 Fitzroy Bright Minds Biosciences Pty Ltd · Tests: BMB-101 Genetic Developmental and Epileptic Encephalopathy Natural History Study for Clinical Trial Readiness NCT07413211n/a1 site📍 New York Weill Medical College of Cornell University · Tests: Observation Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a2 sites📍 Sioux Falls📍 Sydney Sanford Health Home Ultra-long Term EEG Monitoring for Rare Epilepsies and Developmental and Epileptic Encephalopathies NCT06855901NA4 sites📍 Roma📍 Trieste📍 Modena Azienda Ospedaliero-Universitaria di Modena · Tests: Ultra-longterm EEG monitoring at home by means of a scubscalp electrode implant. Study of Patients with Electrical Status Epilepticus in Sleep NCT06792396n/a1 site📍 Colchester East Suffolk and North Essex NHS Foundation Trust A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety NCT07019922Phase 310 sites📍 San Diego📍 Aurora📍 Chicago Praxis Precision Medicines · Tests: 1mg elsunersen, 0.5mg elsunersen A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy NCT07227857Phase 1, Phase 215 sites📍 Orange📍 Boston📍 Rochester Institut de Recherches Internationales Servier · Tests: S230815- Starting dose A, S230815- Dose B, S230815- Dose C, S230815- Dose D A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome NCT05419492Phase 1, Phase 214 sites📍 San Francisco📍 Aurora📍 Miami Encoded Therapeutics · Tests: ETX101 Developmental and Epileptic Encephalopathy of Genetic Etiology: Natural History Through Reuse of Clinical Data NCT06380192n/a23 sites📍 Amiens📍 Angers📍 Besançon Imagine Institute A Study to Evaluate the Safety and Pharmacokinetics of RC001 in Children With Dravet Syndrome NCT07675746EARLY Phase 11 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: RC001 injection-Dose Escalation Cohort, RC001 injection-Fixed Dose Cohort A Fully Remote Feasibility Trial of Phenylbutyrate for SLC6A1-Related Disorders NCT07847918Phase 21 site📍 San Diego Scripps Translational Science Institute · Tests: Glycerol Phenylbutyrate SLC6A1-NDD Prospective Longitudinal Natural History Study NCT07531511n/a3 sites📍 New York📍 Strasbourg📍 Madrid UCB Biopharma SRL A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders NCT06092346n/a1 site📍 Bethesda National Human Genome Research Institute (NHGRI) Genotype, Phenotype, and Disease Progression of Developmental Epileptic Encephalopathy With Onset Before 2 Years of Age NCT06278428n/a2 sites📍 Ho Chi Minh City📍 Ho Chi Minh City Number 2 Children's Hospital, Ho Chi Minh City
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy